Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Primary Liver Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Anti-Infective Agents

Vitamins

Doxorubicin

Liposomal doxorubicin

Leucovorin

Fluorouracil

Raltitrexed

Cisplatin

Oxaliplatin

Liver Extracts

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folic Acid Antagonists

Folate

Vitamin B9

Folinic Acid

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.

The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.

130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Lobaplatin

50 mg per square body surface area was used for monthly transhepatic arterial infusions.

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Oxaliplatin, Leucovorin, fluorouracil

Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Lobaplatin, Raltitrexed

Mingxin Pan, Prof

This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data.

The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results, and the control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization.

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Zhujiang Hospital

Carcinoma

Carcinoma, Hepatocellular

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.

The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.

infusions

Mingxin Pan, Prof.

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected

#excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results, and the control group received postoperative conventional treatment combined with empirical transarterial chemoembolization with Doxorubicin.

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05701436	Liver, Cancer o...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05766605	Hepatocellular ...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05701436	Liver, Cancer o...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital

Spots Global Cancer Trial Database for lobaplatin, raltitrexed